|By PR Newswire||
|April 24, 2014 04:06 PM EDT|
DUBLIN, April 24, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss first quarter 2014 financial results.
Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call:
U.S. Dial-In Number: +1 866 318 8620
International Dial-In Number: +1 617 399 5139
A replay of the conference call will be available through May 15, 2014 and accessible through one of the following telephone numbers and entering the passcode:
Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number: +1 617 801 6888
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz™ (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide). For more information, please visit www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Mar. 29, 2017 05:15 PM EDT Reads: 3,703
Mar. 29, 2017 04:30 PM EDT Reads: 1,624
Mar. 29, 2017 04:15 PM EDT Reads: 3,850
Mar. 29, 2017 04:00 PM EDT Reads: 3,164
Mar. 29, 2017 03:15 PM EDT Reads: 699
Mar. 29, 2017 03:15 PM EDT Reads: 2,637
Mar. 29, 2017 03:15 PM EDT Reads: 271
Mar. 29, 2017 03:15 PM EDT Reads: 2,216
Mar. 29, 2017 02:30 PM EDT Reads: 675
Mar. 29, 2017 02:30 PM EDT Reads: 3,812
Mar. 29, 2017 02:30 PM EDT Reads: 2,274
Mar. 29, 2017 02:15 PM EDT Reads: 3,258
Mar. 29, 2017 01:30 PM EDT Reads: 1,750
Mar. 29, 2017 01:30 PM EDT Reads: 544
Mar. 29, 2017 01:30 PM EDT Reads: 2,250